

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 27, 2020
PDL Changes Effective Date: January 1, 2021



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2021, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	AJOVY AUTOINJECTOR (fremanezumab-vfrm)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	AJOVY SYRINGE (fremanezumab-vfrm)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	EMGALITY PEN (galcanezumab-gnlm)
ANTIRETROVIRALS, INTEGRASE STRAND TRANSFER INHIBITORS	TIVICAY PD (dolutegravir sodium)
ATOPIC DERMATITIS	tacrolimus
BRONCHODILATORS & COPD	ANORO ELLIPTA (umeclidinium/vilanterol)
BRONCHODILATORS, BETA AGONIST	PROAIR HFA (albuterol)
BRONCHODILATORS, BETA AGONIST	VENTOLIN HFA (albuterol)
CYTOKINE & CAM ANTAGONISTS	TALTZ (ixekizumab)
CYTOKINE & CAM ANTAGONISTS	XELJANZ (tofacitinib)
GLUCOCORTICOIDS (Inhaled)	ADVAIR DISKUS (fluticasone /salmeterol)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	OZEMPIC (semaglutide)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	TRULICITY (dulaglutide)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS	INVOKANA (canagliflozin)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS COMBINATIONS	INVOKAMET (canagliflozin/metformin)
MOVEMENT DISORDER AGENTS	AUSTEDO (deutetrabenazine)
PRENATAL VITAMINS	M-NATAL PLUS Tablet

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 27, 2020
PDL Changes Effective Date: January 1, 2021



NEW PREFERRED DRUGS	
PRENATAL VITAMINS	PRETAB Tablet
PRENATAL VITAMINS	VOL-PLUS Tablet
STIMULANTS AND RELATED AGENTS	DYNAVEL XR (amphetamine)
STIMULANTS AND RELATED AGENTS	methylphenidate LA
ULCERATIVE COLITIS & CROHN'S AGENTS	budesonide EC capsule

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANTICONVULSANTS	FINTEPLA (fenfluramine)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	QINLOCK (ripretinib)
ANTIPARKINSON'S AGENTS (Oral)	KYNMOBI FILM (apomorphine)
ANTIRETROVIRALS	RUKOBIA (fostemsavir tromethamine ER)
ANTIRETROVIRALS	TROGARZO (ibalizumab-uiyk)
ANTIVIRALS- INFLUENZA AGENTS	TAMIFLU (oseltamivir phosphate)
BRONCHODILATORS & COPD AGENTS	BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol)
BRONCHODILATORS, BETA AGONIST	albuterol HFA
CYTOKINE & CAM ANTAGONISTS	ARCALYST (rilonacept)
CYTOKINE & CAM ANTAGONISTS	COSENTYX (secukinumab)
GLUCOCORTICOIDS (Inhaled)	fluticasone/salmeterol
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	BYDUREON (exenatide)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	BYETTA (exenatide)
HYPOGLYCEMICS, INSULIN & RELATED AGENTS	LYUMJEV KWIKPEN (insulin lispro)
HYPOGLYCEMICS,INSULIN & RELATED AGENTS	LYUMJEV VIAL (insulin lispro)
MISCELLANEOUS	EVRYSDI (risdiplam)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 27, 2020
PDL Changes Effective Date: January 1, 2021



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
MULTIPLE SCLEROSIS AGENTS	BAFIERTAM (monomethyl fumarate)
MULTIPLE SCLEROSIS AGENTS	ZEPOSIA (ozanimod)
MUSCULAR DYSTROPHY AGENTS	VILTEPSO (viltolarsen)
PRENATAL VITAMINS	TARON-C DHA Capsule
PRENATAL VITAMINS	TRICARE PRENATAL Tablet
ROSACEA TREATMENTS	ZILXI AEROSOL (minocycline)
STIMULANTS AND RELATED AGENTS	APTENSIO XR (methylphenidate)
STIMULANTS AND RELATED AGENTS	QUILLIVANT XR (methylphenidate)
STIMULANTS AND RELATED AGENTS	VYVANSE (lisdexamfetamine)
STIMULANTS AND RELATED AGENTS	VYVANSE CHEWABLE (lisdexamfetamine)
ULCERATIVE COLITIS & CROHN'S AGENTS	ORTIKOS (budesonide)

DRAFT